Anatara Lifesciences (ASX:ANR) Advances GaRP-IBS Trial and Launches Anti-Obesity Project
GaRP-IBS Trial Progress
Anatara Lifesciences has reported that the remaining participants in the GaRP-IBS clinical trial are completing the follow-up period. Headline analysis of Stage 2 is expected in March 2025. The trial currently includes 71 Intent-To-Treat participants, aligning with company expectations. Recruitment remains paused until the initial analysis is assessed and partnering discussions are advanced.
Anti-Obesity Project Approval
The company has received ethics approval for its Anti-Obesity Project, initiating in-vivo proof-of-concept pre-clinical studies. These studies are anticipated to take approximately six months to complete. Anatara has allocated over $250,000 to support the development of an oral medication aimed at assisting weight reduction and maintaining weight control.
Future Outlook
The data from both Stages 1 and 2 of the GaRP-IBS trial will form the basis of the final analysis, encompassing over 100 participants. This final analysis is designed to deliver statistically significant results versus placebo, reinforcing the potential of GaRP as a disease-modifying treatment for gastrointestinal disorders.
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.